372 related articles for article (PubMed ID: 15537499)
1. Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations.
Caballero R; Gómez R; Núñez L; Moreno I; Tamargo J; Delpón E
Cardiovasc Res; 2004 Dec; 64(3):457-66. PubMed ID: 15537499
[TBL] [Abstract][Full Text] [Related]
2. Open channel block of A-type, kv4.3, and delayed rectifier K+ channels, Kv1.3 and Kv3.1, by sibutramine.
Kim SE; Ahn HS; Choi BH; Jang HJ; Kim MJ; Rhie DJ; Yoon SH; Jo YH; Kim MS; Sung KW; Hahn SJ
J Pharmacol Exp Ther; 2007 May; 321(2):753-62. PubMed ID: 17312186
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels.
Gómez R; Núñez L; Caballero R; Vaquero M; Tamargo J; Delpón E
Br J Pharmacol; 2005 Sep; 146(1):146-61. PubMed ID: 15980874
[TBL] [Abstract][Full Text] [Related]
4. Characterization of mibefradil block of the human heart delayed rectifier hKv1.5.
Perchenet L; Clément-Chomienne O
J Pharmacol Exp Ther; 2000 Nov; 295(2):771-8. PubMed ID: 11046117
[TBL] [Abstract][Full Text] [Related]
5. Effects of atorvastatin and simvastatin on atrial plateau currents.
Vaquero M; Caballero R; Gómez R; Núñez L; Tamargo J; Delpón E
J Mol Cell Cardiol; 2007 May; 42(5):931-45. PubMed ID: 17466325
[TBL] [Abstract][Full Text] [Related]
6. Effects of diltiazem and nifedipine on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes.
Gao Z; Sun H; Chiu SW; Lau CP; Li GR
Br J Pharmacol; 2005 Feb; 144(4):595-604. PubMed ID: 15678082
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.
Bachmann A; Gutcher I; Kopp K; Brendel J; Bosch RF; Busch AE; Gögelein H
Naunyn Schmiedebergs Arch Pharmacol; 2001 Nov; 364(5):472-8. PubMed ID: 11692231
[TBL] [Abstract][Full Text] [Related]
8. Papaverine blocks hKv1.5 channel current and human atrial ultrarapid delayed rectifier K+ currents.
Choe H; Lee YK; Lee YT; Choe H; Ko SH; Joo CU; Kim MH; Kim GS; Eun JS; Kim JH; Chae SW; Kwak YG
J Pharmacol Exp Ther; 2003 Feb; 304(2):706-12. PubMed ID: 12538825
[TBL] [Abstract][Full Text] [Related]
9. Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase.
Gong YZ; Ding WG; Wu J; Tsuji K; Horie M; Matsuura H
Eur J Pharmacol; 2008 Dec; 600(1-3):18-25. PubMed ID: 18930721
[TBL] [Abstract][Full Text] [Related]
10. Interaction of riluzole with the closed inactivated state of Kv4.3 channels.
Ahn HS; Kim SE; Jang HJ; Kim MJ; Rhie DJ; Yoon SH; Jo YH; Kim MS; Sung KW; Hahn SJ
J Pharmacol Exp Ther; 2006 Oct; 319(1):323-31. PubMed ID: 16815868
[TBL] [Abstract][Full Text] [Related]
11. Block of cloned Kv4.3 potassium channels by dapoxetine.
Jeong I; Kim SW; Yoon SH; Hahn SJ
Neuropharmacology; 2012 Jun; 62(7):2261-6. PubMed ID: 22192593
[TBL] [Abstract][Full Text] [Related]
12. Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5.
Perchenet L; Hilfiger L; Mizrahi J; Clément-Chomienne O
J Pharmacol Exp Ther; 2001 Sep; 298(3):1108-19. PubMed ID: 11504808
[TBL] [Abstract][Full Text] [Related]
13. Dihydropyridine Ca2+ channel antagonists and agonists block Kv4.2, Kv4.3 and Kv1.4 K+ channels expressed in HEK293 cells.
Hatano N; Ohya S; Muraki K; Giles W; Imaizumi Y
Br J Pharmacol; 2003 Jun; 139(3):533-44. PubMed ID: 12788813
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231.
Ehrlich JR; Ocholla H; Ziemek D; Rütten H; Hohnloser SH; Gögelein H
J Cardiovasc Pharmacol; 2008 Apr; 51(4):380-7. PubMed ID: 18427281
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Kv4.2 channels by a peptide isolated from the venom of the giant bird-eating tarantula Theraphosa leblondi.
Ebbinghaus J; Legros C; Nolting A; Guette C; Celerier ML; Pongs O; Bähring R
Toxicon; 2004 Jun; 43(8):923-32. PubMed ID: 15208026
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide blocks hKv1.5 channels by S-nitrosylation and by a cyclic GMP-dependent mechanism.
Núñez L; Vaquero M; Gómez R; Caballero R; Mateos-Cáceres P; Macaya C; Iriepa I; Gálvez E; López-Farré A; Tamargo J; Delpón E
Cardiovasc Res; 2006 Oct; 72(1):80-9. PubMed ID: 16876149
[TBL] [Abstract][Full Text] [Related]
17. Arachidonic acid potently inhibits both postsynaptic-type Kv4.2 and presynaptic-type Kv1.4 IA potassium channels.
Angelova PR; Müller WS
Eur J Neurosci; 2009 May; 29(10):1943-50. PubMed ID: 19453640
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of myricetin stimulation of vascular L-type Ca2+ current.
Fusi F; Sgaragli G; Saponara S
J Pharmacol Exp Ther; 2005 May; 313(2):790-7. PubMed ID: 15665142
[TBL] [Abstract][Full Text] [Related]
19. The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-go-go-related gene potassium channels stably expressed in HEK 293 cells.
Tang Q; Jin MW; Xiang JZ; Dong MQ; Sun HY; Lau CP; Li GR
Biochem Pharmacol; 2007 Dec; 74(11):1596-607. PubMed ID: 17826747
[TBL] [Abstract][Full Text] [Related]
20. [Electrophysiological correspondence between Kv4.2 current and transient outward potassium current in the cultured rat hippocampal neuron].
Jin HW; Zhang W; Qu LT; Wang XL
Sheng Li Xue Bao; 2003 Dec; 55(6):711-6. PubMed ID: 14695490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
